A minor fat in cell membranes and the raw material for signaling molecules that steer growth and sugar handling. The case for taking it rests on a narrow and divided base: a short trial found a rise in protective cholesterol and a fall in blood fats, a larger one almost no average change. Harms are mostly digestive and dose-dependent. (Full Review)

Protocol

Dose range used in humans

2.8–5.6 g daily

1 g and 3 g daily produced no significant average change; 5 g daily proved intolerable. No dose validated beyond twelve weeks.

Timing

With the largest fat-containing meal

Bile flow and pancreatic phospholipase activity are highest then, and the effect was food-dependent.

Single versus split dosing

Split across two or three meals at 3 g daily and above

Gastrointestinal intolerance tracks the amount of phospholipid reaching the gut at once rather than the daily total.

Time to effect

Fasting triglycerides

2 weeks

A 36% fall at 5.6 g daily taken with food; no significant change at 2.8 g daily.

HDL cholesterol

2 weeks

A 13% rise at 2.8 g daily and 18% at 5.6 g daily in fed, normolipidemic adults.

Response window

12 weeks

The larger trial read out by twelve weeks; an absent response then is unlikely to emerge later.

Benefits

Low: Increased HDL cholesterol and apolipoprotein A-I, conflicted; reduced fasting triglycerides

Speculative: Hepatic fat and body-weight support; support for neural membrane phosphoinositide pools; lower trimethylamine N-oxide burden than choline phospholipids

Contraindications

Documented soy allergy, where the product is soy-derived

Pregnancy and lactation

Chronic kidney disease stage 4–5 (glomerular filtration rate below 30)

Decompensated cirrhosis (Child-Pugh Class B or C)

Severe pancreatic exocrine insufficiency and active inflammatory bowel disease flare

Children and adolescents under 18

Key Interactions

Bile acid sequestrants (cholestyramine, colestipol, colesevelam)

Lipase inhibitors (orlistat)

Narrow-therapeutic-index lipophilic drugs (cyclosporine, tacrolimus, amiodarone, ketoconazole)

Fat-soluble vitamin supplements (A, D, E, K)

Lipid-lowering agents (statins, ezetimibe, fenofibrate, extended-release niacin)

Other phospholipid supplements (lecithin, phosphatidylcholine, phosphatidylserine)

Myo-inositol and D-chiro-inositol

Risk & Side Effects

Medium: Gastrointestinal intolerance, conflicted

Low: Soy protein allergen carryover; altered absorption of fat-soluble drugs and nutrients

Speculative: Omega-6 fatty acid load; lipid peroxidation of stored product; unknown consequences of sustained precursor loading

Monitoring

Marker	Target	Why
HDL cholesterol	55–80 mg/dL	The primary claimed effect
Apolipoprotein A-I	140–200 mg/dL	Particle count behind the HDL number; rose in the positive trial
Triglycerides	Below 80 mg/dL fasting	The second claimed effect and the most food-sensitive marker
Apolipoprotein B	Below 80 mg/dL, below 60 mg/dL where risk is high	Anchors whether an HDL shift changed anything that matters
Alanine aminotransferase	10–26 U/L (men), 10–20 U/L (women)	Detects the fatty liver phenotype and any hepatic response
Gamma-glutamyl transferase	Below 20 U/L (men), below 15 U/L (women)	Sensitive early marker of hepatic and biliary stress
High-sensitivity C-reactive protein	Below 1.0 mg/L	Confirms an inflammatory state is not confounding lipid changes

Cadence: Baseline, then lipid panel and liver enzymes at 4 weeks and again at 12 weeks, then every 6–12 months if continued

Qualitative Assessment

Stool consistency and frequency, the earliest signal that the dose exceeds tolerance
Bloating, nausea or upper abdominal fullness in the hours after dosing
Appetite and body weight, given the animal signal on weight gain
Energy through the afternoon, as an unblinded but sensitive personal marker
Any change in tolerance of fatty meals, which would suggest altered biliary handling

Phosphatidylinositol for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment